These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28316003)

  • 1. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gammaplex
    Wasserman RL
    Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
    Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
    Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
    Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
    Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
    J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075).
    Dash CH; Gillanders KR; Stratford Bobbitt ME; Gascoigne EW; Leach SJ
    PLoS One; 2014; 9(6):e96600. PubMed ID: 24892422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
    van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
    Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
    Kriván G; Borte M; Soler-Palacin P; Church JA; Csurke I; Harris JB; Lieberman JA; Melamed IR; Moy JN; Simon R; Aigner S; Lentze S; Staiger C
    J Clin Immunol; 2023 Apr; 43(3):557-567. PubMed ID: 36383294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
    Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
    Front Immunol; 2019; 10():40. PubMed ID: 30778345
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.
    Moy JN; Scharenberg AM; Stein MR; Suez D; Roberts RL; Levy RJ; Ballow M; Fasano MB; Dash CH; Leach SJ
    Clin Exp Immunol; 2010 Dec; 162(3):510-5. PubMed ID: 21070209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
    Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
    Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
    Kriván G; Borte M; Harris JB; Lumry WR; Aigner S; Lentze S; Staiger C
    Vox Sang; 2022 Oct; 117(10):1153-1162. PubMed ID: 35944615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
    Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
    Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
    Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
    Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.